Skip to content

Study of Serum Tumor Markers of HBV Associated HCC

Study of Serum Tumor Markers of HBV Associated HCC

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05825196
Enrollment
164
Registered
2023-04-24
Start date
2023-05-01
Completion date
2025-12-31
Last updated
2023-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HCC

Keywords

HBV related HCC

Brief summary

In this study, the investigators will detect the expression of four potential HBV-related HCC biomarkers: PGIR,FAM3C,LAMB1 and SDC4 in tumor tissues and peripheral blood, to explore the specific molecular markers for the early diagnosis of HBV-related HCC.

Detailed description

Paired hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) and adjacent liver tissues were selected, and the mRNA and protein expressions of the PGIR,FAM3C,LAMB1 and SDC4 biomarkers in tissues were detected by RT-PCR, western Blot and immunohistochemical analysis. At the same time, healthy subjects were selected as the control group, and mRNA and protein expression levels of the above molecules in blood were detected by RT-PCR and ELISA. At the same time, the correlation between the above biomarkers and the clinical data of patients, such as diagnosis, pathological grading, recurrence, metastasis and survival time was statistically analyzed.

Interventions

DIAGNOSTIC_TESTtumor tissue and blood tests

In this study, we need to collect an extra tube of blood for routine testing and the tissue after completion of pathological examination.

Sponsors

Qianfoshan Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* No local or systemic treatment was performed before surgery. The patients were finally diagnosed with HBV-related HCC by examination and imaging examination, and the clinicopathologic data were complete.

Exclusion criteria

* Patients with benign liver diseases, such as hepatic cysts and hepatic hemangiomas, or have tumors other than HBV-related HCC.

Design outcomes

Primary

MeasureTime frameDescription
Detection of RNA and protein for diagnosis6 monthsDetect the content of the RNA and protein in tumor and serum

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026